ChromaDex Corporation (CDXC)
5.54
0.04 (0.73%)
At close: Mar 04, 2025, 12:56 PM
No 1D chart data available
| Bid | 5.53 |
| Market Cap | 422.78M |
| Revenue (ttm) | 101.55M |
| Net Income (ttm) | 1.49M |
| EPS (ttm) | 0.02 |
| PE Ratio (ttm) | 276.75 |
| Forward PE | 44.15 |
| Analyst | Strong Buy |
| Ask | 5.54 |
| Volume | 410,283 |
| Avg. Volume (20D) | 445,241 |
| Open | 5.54 |
| Previous Close | 5.50 |
| Day's Range | 5.27 - 5.58 |
| 52-Week Range | 1.57 - 7.97 |
| Beta | 2.21 |
About CDXC
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-b...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 25, 2008
Employees 106
Stock Exchange NASDAQ
Ticker Symbol CDXC
Website https://www.chromadex.com
Analyst Forecast
According to 2 analyst ratings, the average rating for CDXC stock is "Strong Buy." The 12-month stock price forecast is $8, which is an increase of 44.53% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
ChromaDex Corporation is scheduled to release its earnings on Mar 4, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+14.4%
ChromaDex shares are trading higher after Roth MKM...
Unlock content with
Pro Subscription
4 months ago
+67.91%
ChromaDex shares are trading higher after the company reported a year-over-year increase in Q3 EPS results and raised its FY24 revenue guidance.
